Barinthus Biotherapeutics (BRNS) Research & Development (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Research & Development came in at $3.6 million in Q1 2026, down 56.66% YoY from $8.3 million in Q1 2025, and down 8.6% on a QoQ basis from $3.9 million in Q4 2025.
Barinthus Biotherapeutics (BRNS) Research & Development (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Research & Development data on file, last reported at $3.6 million in Q1 2026.
- Quarterly Research & Development fell 56.66% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.9 million (down 47.04% YoY) and the FY2025 annual result came in at $25.6 million, down 39.47% from the prior year.
- Research & Development fell to $3.6 million in Q1 2026, from $3.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $15.1 million in Q3 2023 to a low of $3.6 million in Q1 2026.
- A 5-year average of $9.3 million and a median of $9.7 million in 2022 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development jumped 132.13% — and 2026, when it tumbled 56.66%.
- Tracing BRNS's Research & Development over 5 years: stood at $12.2 million in 2022, then tumbled by 47.7% to $6.4 million in 2023, then surged by 30.39% to $8.3 million in 2024, then sank by 52.7% to $3.9 million in 2025, then fell by 8.6% to $3.6 million in 2026.
- The last three Research & Development figures came in at $3.6 million (Q1 2026), $3.9 million (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - | 3.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.92 Mn |
| Mar 31, 2026 | 3.59 Mn |
| Dec 31, 2025 | 3.93 Mn |
| Sep 30, 2025 | 5.39 Mn |
| Jun 30, 2025 | 7.95 Mn |
| Mar 31, 2025 | 8.29 Mn |
| Dec 31, 2024 | 8.31 Mn |
| Sep 30, 2024 | 11.14 Mn |
| Jun 30, 2024 | 11.66 Mn |
| Mar 31, 2024 | 11.13 Mn |
| Dec 31, 2023 | 6.37 Mn |
| Sep 30, 2023 | 15.14 Mn |
| Jun 30, 2023 | 13.54 Mn |
| Mar 31, 2023 | 9.81 Mn |
| Dec 31, 2022 | 12.19 Mn |
| Sep 30, 2022 | 9.74 Mn |
| Jun 30, 2022 | 9.72 Mn |
| Mar 31, 2022 | 10.70 Mn |
| Dec 31, 2021 | 6.88 Mn |
| Sep 30, 2021 | 4.37 Mn |